• N Ortiz-Brüchle, M Muders, M Toma, I Esposito, A Hartmann, R Stöhr, H Reis, P Wild, J Köllermann, F Bremmer, J Leichsenring, A Stenzinger, S Merkelbach-Bruse, S Kirfel, S Perner, N Hartmann, W Roth, A Jung, T Kirchner, K Schwamborn, N Pfarr, E Dahl, R Knüchel, and N T Gaisa.
• Institut für Pathologie, Uniklinikum, RWTH Aachen, Pauelsstraße 30, 52074, Aachen, Deutschland.
• Urologe A. 2020 Mar 1; 59 (3): 318-325.

BackgroundTechnical advancement and availability of high-throughput analysis has advanced molecular subtyping of most cancers. Thus, new possibilities for precision oncology have emerged.AimTherefore, we aimed to collect data regarding availability and use of next generation sequencing (NGS) for urothelial cancer within the uropathology working group of the German Society of Pathology.MethodsWe collected data by questionnaires and additionally asked for sequencing results of bladder cancers in the participating institutions.ResultsA total of 13 university-affiliated institutes of pathology took part in the survey. All university institutes offer NGS-based molecular panel diagnostics and provide panels covering between 15 and 170 genes. Altogether, only 20 bladder cancers were sequenced in routine diagnostics and for 10 cancers potential targeted treatment options were available.DiscussionSo far, despite availability of NGS diagnostics at university institutes of pathology, only few bladder cancer samples have been sequenced. Based on current data from the molecular subtyping of bladder cancers, we recommend a step-by-step protocol with basic immunohistochemistry analysis and subsequent subtype-dependent analyses, e.g., alterations of the fibroblast growth factor receptors (FGFR) or comprehensive gene panel analyses.

15 keywords...

hide…